In addition, FDA agreed to submit to the district court and to the NRDC status reports every 6 months (until each monograph is completed) containing a description of the actions taken by FDA to meet ...

On Thursday the Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter monograph drug products for the ...

SILVER SPRING, Md., Nov. 7, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in ...

SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or ...

The FDA is urging lawmakers to reauthorize a key user fee program that could expand access to over the counter medications, reducing barriers to treatment. At a recent hearing before the Senate Health ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window When ...

The FDA committee unanimously concluded the data do not support oral phenylephrine’s effectiveness as a nasal decongestant. The Food and Drug Administration (FDA) announced a proposal to remove oral ...

Lawmakers are working on legislation to lower market barriers for new sunscreens, an effort to bring the U.S. in line with ...

Please provide your email address to receive an email when new articles are posted on . An FDA review found that oral phenylephrine is not effective in treating nasal congestion. The proposal is based ...